IRIS
BERGANTINI, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 11.629
NA - Nord America 9.609
AS - Asia 4.921
SA - Sud America 943
AF - Africa 149
OC - Oceania 22
Continente sconosciuto - Info sul continente non disponibili 6
AN - Antartide 1
Totale 27.280
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.407
RU - Federazione Russa 2.969
IT - Italia 2.863
SG - Singapore 1.866
IE - Irlanda 1.500
GB - Regno Unito 1.421
CN - Cina 1.289
BR - Brasile 808
DE - Germania 715
SE - Svezia 652
HK - Hong Kong 546
FR - Francia 406
FI - Finlandia 405
VN - Vietnam 286
IN - India 247
KR - Corea 211
NL - Olanda 133
ES - Italia 123
UA - Ucraina 122
CA - Canada 107
JP - Giappone 79
CZ - Repubblica Ceca 69
MX - Messico 67
PL - Polonia 67
BD - Bangladesh 56
CI - Costa d'Avorio 56
TR - Turchia 53
AT - Austria 46
AR - Argentina 43
ZA - Sudafrica 42
IR - Iran 37
IQ - Iraq 33
EC - Ecuador 23
PK - Pakistan 23
CH - Svizzera 22
AE - Emirati Arabi Uniti 21
UZ - Uzbekistan 21
SA - Arabia Saudita 20
MA - Marocco 19
AU - Australia 17
PH - Filippine 17
BE - Belgio 16
CL - Cile 14
PE - Perù 14
ID - Indonesia 13
LT - Lituania 13
VE - Venezuela 13
KZ - Kazakistan 11
AZ - Azerbaigian 10
CO - Colombia 10
EE - Estonia 10
IL - Israele 10
PT - Portogallo 10
BG - Bulgaria 9
EG - Egitto 8
GE - Georgia 8
JM - Giamaica 8
LV - Lettonia 8
RO - Romania 8
HU - Ungheria 7
JO - Giordania 7
KE - Kenya 7
KG - Kirghizistan 7
PY - Paraguay 7
DK - Danimarca 6
EU - Europa 6
LB - Libano 6
LK - Sri Lanka 6
PA - Panama 6
MY - Malesia 5
NG - Nigeria 5
UY - Uruguay 5
BO - Bolivia 4
CY - Cipro 4
HR - Croazia 4
LA - Repubblica Popolare Democratica del Laos 4
MK - Macedonia 4
NO - Norvegia 4
OM - Oman 4
TN - Tunisia 4
TW - Taiwan 4
AM - Armenia 3
CR - Costa Rica 3
DO - Repubblica Dominicana 3
GR - Grecia 3
NP - Nepal 3
RS - Serbia 3
BY - Bielorussia 2
DZ - Algeria 2
ET - Etiopia 2
LU - Lussemburgo 2
MD - Moldavia 2
NR - Nauru 2
NZ - Nuova Zelanda 2
QA - Qatar 2
SN - Senegal 2
SV - El Salvador 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
AL - Albania 1
Totale 27.259
Salva come PNG Salva come JPEG
Città #
Dallas 2.218
Dublin 1.473
Singapore 1.245
Southend 1.187
Moscow 912
Ashburn 774
Santa Clara 756
Chandler 623
Fairfield 617
Hong Kong 530
Siena 474
Beijing 401
Munich 348
Lastra a Signa 340
Milan 294
Hefei 267
Helsinki 267
Los Angeles 237
Houston 234
Woodbridge 230
New York 226
Wilmington 226
Seattle 215
Seoul 204
Princeton 186
Florence 184
Cambridge 179
Ann Arbor 126
Rome 118
São Paulo 90
Chicago 87
Shanghai 79
Bengaluru 72
Ho Chi Minh City 72
Jacksonville 71
Redondo Beach 67
Dong Ket 64
Turku 64
Buffalo 63
Fremont 63
Tokyo 63
Lauterbourg 62
Nuremberg 61
Málaga 59
San Mateo 59
Warsaw 58
Abidjan 56
Lappeenranta 56
Boardman 54
Düsseldorf 52
Hanoi 51
San Diego 51
London 50
Portsmouth 48
Dearborn 47
The Dalles 46
Brno 40
Council Bluffs 38
Brooklyn 37
Stockholm 37
Washington 34
Johannesburg 33
Frankfurt am Main 31
Chennai 30
Brescia 29
Denver 29
Toronto 29
Atlanta 28
Montreal 28
Phoenix 28
Boston 26
Poplar 25
Gavirate 24
Olomouc 23
Padova 23
Rio de Janeiro 23
San Francisco 23
Naples 22
Vienna 22
Mexico City 21
Dhaka 20
Salt Lake City 20
Agliana 19
Hyderabad 19
Manchester 19
Newark 19
Orem 19
Tashkent 18
Amsterdam 17
Guangzhou 17
Querétaro 17
Tarazona 17
Ankara 16
Brasília 16
Brussels 16
Livorno 16
Mumbai 16
Belo Horizonte 15
Zhengzhou 15
Tampa 14
Totale 17.784
Salva come PNG Salva come JPEG
Nome #
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population 545
A first update on mapping the human genetic architecture of COVID-19 539
Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study 455
Genetic mechanisms of critical illness in COVID-19 332
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males 328
An explainable model of host genetic interactions linked to COVID-19 severity 324
Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis 317
Alveolar concentration of nitric oxide as a prognostic biomarker in idiopathic pulmonary fibrosis 309
Peripheral biomarkers' panel for severe COVID-19 patients 291
Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research 286
Pathogen-sugar interactions revealed by universal saturation transfer analysis 269
Mapping the human genetic architecture of COVID-19 262
Antithrombin III as predictive indicator of survival in IPF patients treated with Nintedanib: a preliminary study 260
Prognostic Biomarkers of Sarcoidosis: A Comparative Study of Serum Chitotriosidase, ACE, Lysozyme, and KL-6 259
Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity 258
Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib 246
Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males 245
Evaluation of multiple-flows exhaled nitric oxide in idiopathic and non-idiopathic interstitial lung disease 240
The effect of cigarette smoking on bronchoalveolar lavage protein profiles from patients with different interstitial lung diseases 238
Adiponectin and leptin levels in idiopathic pulmonary fibrosis: A new method for BAL and serum assessment 232
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients 232
Immune modulatory effects of novel monoclonal antibodies target therapies in severe eosinophilic asthma patients 228
A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting 227
Carriers of ADAMTS13 Rare Variants Are at High Risk of Life-Threatening COVID-19 225
Serum amyloid A in patients with idiopathic pulmonary fibrosis 221
Rituximab Therapy in Interstitial Lung Disease associated with Rheumatoid Arthritis 219
Prognostic bioindicators in severe COVID-19 patients 217
SARS-CoV-2 susceptibility and COVID-19 disease severity are associated with genetic variants affecting gene expression in a variety of tissues 216
Alveolar nitric oxide is related to periostin levels in idiopathic pulmonary fibrosis 215
Ceruloplasmin and oxidative stress in severe eosinophilic asthma patients treated with Mepolizumab and Benralizumab 214
Adaptive immune system in pulmonary sarcoidosis - comparison of peripheral and alveolar biomarkers 214
Serial KL-6 measurements in COVID-19 patients 212
AB0611 Neutrophil extracellular traps and interstitial lung disease in ANCA-associated vasculitis: a scoping review 209
BAL biomarkers’ panel for differential diagnosis of interstitial lung diseases 204
A real-life experience with ImmunoCAP ISAC: the advantages of a new diagnostic method 204
Galactin-1, 3 and 9: Potential biomarkers in idiopathic pulmonary fibrosis and other interstitial lung diseases 204
Severe COVID-19 in hospitalized carriers of single CFTR pathogenic variants 204
NK and NKT-like cells in granulomatous and fibrotic lung diseases 203
Alveolar nitric oxide as a biomarker of COVID-19 lung sequelae: A pivotal study 202
Serum KL-6 concentrations as a novel biomarker of severe COVID-19 201
Bronchoalveolar lavage and serum KL-6 concentrations in chronic hypersensitivity pneumonitis: correlations with radiological and immunological features 200
Gain- and Loss-of-Function CFTR Alleles Are Associated with COVID-19 Clinical Outcomes 197
BAL and serum multiplex lipid profiling in idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis 195
Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena 193
Regulatory T Cells in Severe Persistent Asthma in the Era of Monoclonal Antibodies Target Therapies 191
C9orf72 intermediate repeats confer genetic risk for severe covid-19 pneumonia independently of age 191
Serum amyloid A: A potential biomarker of lung disorders 189
Serum concentrations of Krebs von den Lungen-6 in different COVID-19 phenotypes 188
A multicenter approach to evaluate omalizumab effectiveness in Samter’s triad 186
Immune-Checkpoint Expression on CD4, CD8 and NK Cells in Blood, Bronchoalveolar Lavage and Lymph Nodes of Sarcoidosis 184
Krebs von den Lungen-6 as Disease Severity Marker for COVID-19 Patients: Analytical Verification and Quality Assessment of the Tosoh AIA-360 Compared to Lumipulse G600II 184
WES profiling of COVID-19 183
Efficacy of baricitinib in treating rheumatoid arthritis: Modulatory effects on fibrotic and inflammatory biomarkers in a real-life setting 181
Alteration of Immune-checkpoint after specific stimulation with CMV antigens in pre-LTx patients 177
Altered serum concentrations of IL-8, IL-32 and IL-10 in patients with lung impairment 6 months after COVID-19 176
BAL Proteomic Signature of Lung Adenocarcinoma in IPF Patients and Its Transposition in Serum Samples for Less Invasive Diagnostic Procedures 175
Effects of rituximab therapy on B cell differentiation and depletion 175
Regulatory and Effector Cell Disequilibrium in Patients with Acute Cellular Rejection and Chronic Lung Allograft Dysfunction after Lung Transplantation: Comparison of Peripheral and Alveolar Distribution 175
Idiopathic Pulmonary Fibrosis Serum proteomic analysis before and after nintedanib therapy 174
Peripheral and alveolar biomarkers of fibrotic hypersensitivity pneumonitis 173
The Role of Urinary Calcium and Chitotriosidase in a Cohort of Chronic Sarcoidosis Patients 168
Regulatory T cell monitoring in severe eosinophilic asthma patients treated with mepolizumab 168
Brain neuronal and glial damage during acute COVID-19 infection in absence of clinical neurological manifestations 167
Ultra-rare RTEL1 gene variants associate with acute severity of COVID-19 and evolution to pulmonary fibrosis as a specific long COVID disorder 167
Clinical and molecular characterization of COVID-19 hospitalized patients 166
Krebs von den Lungen-6 as biomarker for disease severity assessment in interstitial lung disease: a comprehensive review 164
Serum CD59: a novel biomarker of idiopathic pulmonary fibrosis? 160
Systematic review and metanalysis of oncomarkers in ipf patients and serial changes of oncomarkers in a prospective italian real-life case series 159
Peripheral lymphocyte subset monitoring in COVID-19 Italian patients 158
Prognostic role of KL-6 in lymphangioleiomyomatosis patients 157
Multi-Omics Integrative Approach of Extracellular Vesicles: A Future Challenging Milestone 156
A Comprehensive Review of Sarcoidosis Treatment for Pulmonologists 155
Immunologic responses to antifibrotic treatment in IPF patients 153
Protective role of a TMPRSS2 variant on severe COVID-19 outcome in young males and elderly women 153
Common molecular pathways targeted by nintedanib in cancer and IPF: a bioinformatic study 152
Oxygen Therapy during Exercise in Patients with Interstitial Lung Diseases 151
Proteomic characterization of idiopathic pulmonary fibrosis patients: stable versus acute exacerbation 151
Collagen Type IV Alpha 5 Chain in Bronchiolitis Obliterans Syndrome After Lung Transplant: The First Evidence 150
Differential redox proteomic profiles of serum from severe asthma patients after one month of Benralizumab and Mepolizumab treatment 149
Serum Proteomic Profile of Asthmatic Patients after Six Months of Benralizumab and Mepolizumab Treatment 149
The Effects of Interstitial Lung Diseases on Alveolar Extracellular Vesicles Profile: A Multicenter Study 148
The pathogenetic mechanisms of cough in idiopathic pulmonary fibrosis 147
Mepolizumab and Benralizumab in Severe Eosinophilic Asthma: Preliminary Results of a Proteomic Study 146
Utility of serological biomarker' panels for diagnostic accuracy of interstitial lung diseases 146
CD103 Expression on Regulatory and Follicular T Cells in Lymph Nodes, Bronchoalveolar Lavage Fluid and Peripheral Blood of Sarcoidosis Patients 144
Whole-genome sequencing reveals host factors underlying critical COVID-19 143
Serial investigation of Angiotensin-Converting Enzyme in sarcoidosis patients treated with Angiotensin-Converting Enzyme Inhibitor 143
Cytological analysis of bronchoalveolar lavage fluid in asbestos-exposed workers: BALF features in asbestos exposed workers 142
Metabolic Dysregulation in Idiopathic Pulmonary Fibrosis 137
Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study 137
Cytokine profiles in the detection of severe lung involvement in hospitalized patients with COVID-19: The IL-8/IL-32 axis 135
Interstitial lung disease associated with psoriatic arthritis: a new disease entity? 134
Characterization of NKG2-A/-C, Kir and CD57 on NK Cells Stimulated with pp65 and IE-1 Antigens in Patients Awaiting Lung Transplant 133
Pleuroparenchymal fibroelastosis in patients affected by systemic sclerosis: What should the rheumatologist do? 132
Serum Concentrations of KL-6 in Patients with IPF and Lung Cancer and Serial Measurements of KL-6 in IPF Patients Treated with Antifibrotic Therapy 131
The Role of Galectins in Chronic Lung Allograft Dysfunction 131
Bronchoalveolar-Lavage-Derived Fibroblast Cell Line (B-LSDM7) as a new protocol for investigating the mechanisms of idiopathic pulmonary fibrosis 130
Prevalence of myositis specific and associated antibodies in a cohort of patients affected by idiopathic NSIP and no hint of inflammatory myopathies 129
Neutrophil-to-lymphocyte ratio in bronchoalveolar lavage from IPF patients: a novel prognostic biomarker? 129
Rituximab-induced hypogammaglobulinaemia in patients affected by idiopathic inflammatory myopathies: a multicentre study 128
Totale 20.091
Salva come PNG Salva come JPEG
Categoria #
all - tutte 101.355
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 101.355
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.445 0 0 0 0 0 246 160 256 217 147 217 202
2021/20222.306 175 268 201 159 113 100 95 104 101 295 262 433
2022/20232.707 175 294 334 266 155 479 283 236 183 117 111 74
2023/20243.095 119 95 316 163 158 661 869 147 43 103 119 302
2024/20256.894 603 268 757 395 788 424 381 419 535 350 627 1.347
2025/20269.828 1.057 1.926 1.751 1.859 3.101 134 0 0 0 0 0 0
Totale 28.057